tiprankstipranks
Trending News
More News >

Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results

Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results

Confident Investing Starts Here:

The latest update is out from Barinthus Biotherapeutics ( (BRNS) ).

Barinthus Biotherapeutics and Arbutus Biopharma have reported promising data from their IM-PROVE II trial, showing that adding nivolumab to their treatment regimen significantly increased the loss of hepatitis B surface antigen (HBsAg) in chronic hepatitis B patients. This innovative approach, combining the RNAi therapeutic imdusiran with VTP-300 and low-dose nivolumab, demonstrated enhanced immune responses and was generally well tolerated. Such developments indicate potential advancements in achieving functional cures for chronic hepatitis B, which could be a significant breakthrough for investors interested in biopharmaceutical innovations.

See more data about BRNS stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App